Clinical and Radiological Outcomes of the ROMAX Hip Resurfacing System

Not yet recruiting

• Conditions: Arthritis (Hip); Hip Dysplasia, Congenital

• Registration Number: NCT06775704
• Lead Sponsor: Medacta International SA

Brief Summary

The goal of this observational study is to collect clinical and radiological data to monitor the safety and performance of the ROMAX hip resurfacing system. The main parameter that will be measured is the rate of revisions at 10 years.

Detailed Description

This single-center, post-market, prospective, longitudinal, and uncontrolled cohort study aims to evaluate the survival rate of the Medacta ROMAX hip resurfacing system, particularly focusing on dislocations and the potential consequences of wear over a 10-year period. Additionally, the study will assess clinical performance through patient-reported outcomes (PROMs) and analyze the migration behavior of the device using the CTMA method in a subgroup of 40 patients. The study will include a total of 150 cases, with 40 patients undergoing CTMA analysis at 3 years post-surgery. Eligible patients will be informed during preoperative visits and included upon signing the consent form, prior to surgery. Participation in the CTMA subgroup is optional and does not affect overall study inclusion. Follow-ups will be conducted at 3 months, 1, 3, 5, and 10 years. Data collection will include clinical scores, clinical and radiological data related to preoperative and postoperative status, and perioperative surgical details.

Study Timeline

• Study First Submitted: 2025-01-09
• Study First Submitted QC: 2025-01-09
• Study First Posted: 2025-01-15
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-07
• Last Update Posted: 2025-05-08
• Study Start: 2025-06-01
• Primary Completion: 2037-04-01
• Study Completion: 2037-04-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Patients eligible for hip resurfacing, suitable for the implantation of a Medacta ROMAX hip resurfacing system according to the manufacturer's defined indication for use.
• Aged between 18 and 65 years at the time of surgery.
• Ability and willingness to provide written informed consent for participation.

Exclusion Criteria

• Active infection
• BMI > 40
• Mental illness, when the known pathology is likely to compromise the patient's ability to consent, affect the patient's assessment of their progress, or complete follow-up appointments and exams.
• Significantly deformed anatomy (at the surgeon's discretion)
• Osteomalacia where the fixation of an uncemented implant is contraindicated
• Active rheumatoid arthritis
• Osteoporosis
• Metabolic disorders likely to impair bone formation and for which the fixation of an uncemented implant is contraindicated
• Muscle atrophy or neuromuscular disease
• Known allergy or hypersensitivity to the implant material
• Any patient who cannot or does not wish to give informed consent to participate in the study
• Patients whose chances of regaining independent mobility would be compromised by known concomitant medical issues.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Implant survival	10 years	Survival of the implant through Kaplan-Meier analysis based on revisions

Secondary Outcome Measures

Name	Time	Method
CT-micromotion analysis (CTMA)	3 months, 1 year, 3 years	CT-based evaluation of implant movement and wear. Will be performed on a subgroup of patients (40)
Forgotten Joint Score (FJS)	3 months, 1 year, 3 years, 5 years, 10 years	Patient-reported outcome measure that evaluates joint dysfunction. It ranges from 0 to 100, with higher scores indicating better outcomes
Oxford Hip Score (OHS)	3 months, 1 year, 3 years, 5 years, 10 years	Patient-reported outcome measure designed to assess hip function and pain. It ranges from 0 to 48, with higher scores indicating better function and less pain.
Radiologic Evaluation	3 months, 1 year, 3 years, 5 years, 10 years	Assessment of implant positioning and radiographic appearence.
Harris Hip Score (HHS)	3 months, 1 year, 3 years, 5 years, 10 years	Measure of dysfunction ranging from 0 to 100, where higher values represent better outcomes.
Postel-Merle d'Aubigné Score (PMA)	3 months, 1 year, 3 years, 5 years, 10 years	Clinical rating system used to assess hip function. It ranges from 0 to 18, with higher scores indicating better hip function and fewer limitations in activities.
UCLA Activity Scale	3 months, 1 year, 3 years, 5 years, 10 years	Questionnaire assessing physical activity level from 1 (low) to 10 (high).
HOOS (Hip injury and Osteoarthritis Outcome Score) Symptoms subscale	3 months, 1 year, 3 years, 5 years, 10 years	Patient-reported outcome measure comprising 5 questions assessing hip joint symptoms and stiffness. It ranges from 0 to 100, with higher values indicating better outcomes.

Trial Locations

Locations (1)

Centre Hospitalier Universitaire de Lille; 🇫🇷 Lille, France